{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:13:50Z","timestamp":1789146830584,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022739","name":"Hospital del Mar Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109560","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:31:16Z","timestamp":1786145476000},"page":"109560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study"],"prefix":"10.1016","volume":"220","author":[{"given":"Laura","family":"Masfarr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Parreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-0580","authenticated-orcid":false,"given":"Natalia","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-9205","authenticated-orcid":false,"given":"Nil","family":"Navarro-Gorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Marse","family":"Fabregat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Gomez","family":"Bellvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia Ari\u00f1o","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3081-8405","authenticated-orcid":false,"given":"Antonia Company","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite Martinez","family":"Aguillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Arasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Morilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-8454","authenticated-orcid":false,"given":"Sergi","family":"Clave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-6730","authenticated-orcid":false,"given":"Alvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor Azkarate","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-7519","authenticated-orcid":false,"given":"Edurne","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109560_b0005","article-title":"Cancer statistics 2026","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109560_b0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","article-title":"Scientific advances in Lung Cancer 2015","volume":"11","author":"Tsao","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109560_b0015","article-title":"Front","volume":"11","author":"Shen","year":"2022","journal-title":"Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109560_b0020","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109560_b0025","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109560_b0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109560_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-ocurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109560_b0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11-and KEAP1- mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109560_b0045","article-title":"Impact of KRAS codon subtypes from a randomized phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Nature","volume":"113","author":"Janne","year":"2015","journal-title":"Oncol"},{"issue":"10378","key":"10.1016\/j.lungcan.2026.109560_b0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib Versus Docetaxel for previously Treated Non-Small-Cell Lung Cancer with KRASG12C Mutation: a Randomised, Open-Label, phase 3 Trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"10503","key":"10.1016\/j.lungcan.2026.109560_b0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109560_b0060","article-title":"Front","volume":"11","author":"Corral de la Fuente","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.lungcan.2026.109560_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djr523","article-title":"Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome","volume":"104","author":"Ihle","year":"2012","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2026.109560_b0070","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-17-3438","article-title":"Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-driven Mouse Model of Lung Cancer","volume":"24","author":"Li","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109560_b0075","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and Molecular Correlates of PD-L1 Expression in patients with Lung Adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann. Oncol. off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109560_b0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-Ras Mutation Subtypes in NSCLC and Associated Co-Occuring Mutations in Other Oncogenic Pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109560_b0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109560_b0090","doi-asserted-by":"crossref","unstructured":"Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer. 2020 Jan 15;126(2):260-270. doi: 10.1002\/cncr.32468. Epub 2019 Nov 6. PMID: 31691957; PMCID: PMC7372560.","DOI":"10.1002\/cncr.32468"},{"key":"10.1016\/j.lungcan.2026.109560_b0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109560_b0100","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/cncr.34731","article-title":"Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy","volume":"129","author":"Bironzo","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109560_b0105","doi-asserted-by":"crossref","unstructured":"Biton J, Mansuet-Lupo A, Pecuchet N, et al. TP53, STK11, and EGFR mutations predict tumour immune profile and the response to antiPD-1 in lung adenocarcinoma. Clin Cancer Res 2018 Nov 15;24(22):5710e23. https:\/\/doi.org\/10.1158\/1078- 0432.CCR-18-0163. Epub 2018 May 15. PMID: 29764856.","DOI":"10.1158\/1078-0432.CCR-18-0163"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109560_b0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109560_b0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2020.09.004","article-title":"KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma","volume":"149","author":"Gao","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109560_b0120","doi-asserted-by":"crossref","unstructured":"Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 2019 Sep;9(5):871-879. doi: 10.1016\/j.apsb.2019.03.002. Epub 2019 Mar 6. PMID: 31649840; PMCID: PMC6804475.","DOI":"10.1016\/j.apsb.2019.03.002"},{"key":"10.1016\/j.lungcan.2026.109560_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108421","article-title":"Real-World outcomes of Non-small cell lung cancer patients harbouringKRAS G12CandKRAS G12Dmutations","volume":"201","author":"Shahnam","year":"2025","journal-title":"Lung Cancer (amsterdam, Netherlands)."},{"issue":"10454","key":"10.1016\/j.lungcan.2026.109560_b0130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109560_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102957","article-title":"Dealing with KRAS G12C Inhibition in Non-Small Cell Lung Cancer (NSCLC) - Biology, Clinical results and Future Directions","volume":"137","author":"Attili","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109560_b0140","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.57187\/s.3695","article-title":"Prognostic Value of KRAS G12C in Advanced Non-Small Cell Lung Cancer with High PD-L1 Expression Treated with Upfront Immunotherapy: a Systematic Review and Meta-Analysis","volume":"154","author":"Erhart","year":"2024","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.lungcan.2026.109560_b0145","doi-asserted-by":"crossref","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016\/S0140-6736(18)32409-7. Epub 2019 Apr 4. PMID: 30955977.","DOI":"10.1016\/S0140-6736(18)32409-7"},{"issue":"14","key":"10.1016\/j.lungcan.2026.109560_b0150","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10274","key":"10.1016\/j.lungcan.2026.109560_b0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109560_b0160","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/oncolo\/oyad197","article-title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-Pd(l)-1 Blockade in KRASG12C-mutant Non-Small Cell Lung Cancer","volume":"28","author":"Elkrief","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109560_b0165","doi-asserted-by":"crossref","unstructured":"Houda, I. et al. 1851MO Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) \u226550%: Open-label, phase III, randomized trial (PAULIEN). Annals of Oncology, Volume 36, S996.","DOI":"10.1016\/j.annonc.2025.08.2475"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109560_b0170","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3390\/cancers14194933","article-title":"Clinical and Molecular Features of KRAS-Mutated Lung Cancer patients Treated with Immune Checkpoint Inhibitors","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109560_b0175","doi-asserted-by":"crossref","unstructured":"Markovi\u0107 F, Milin-Lazovi\u0107 J, Nikoli\u0107 N, Golubovi\u0107 A, Stjepanovi\u0107 M, Konti\u0107 M. KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.Curr Oncol. 2025;32(6):365. Published 2025 Jun 19. doi:10.3390\/curroncol32060365.","DOI":"10.3390\/curroncol32060365"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109560_b0180","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cbin.11524","article-title":"KRAS G12V mutation upregulates PD-L1 expression via TGF-\u03b2\/EMT signaling pathway in human non-small-cell lung cancer","volume":"45","author":"Pan","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.lungcan.2026.109560_b0185","unstructured":"T\u00f8nnesen EMT, Stougaard M, Meldgaard P, Lade-Keller J. Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy. J Clin Pathol. 2022 Nov 21:jcp-2022-208574. doi: 10.1136\/jcp2022-208574. Epub ahead of print. PMID: 36410939."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109560_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower 150 trial","volume":"10","author":"West","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109560_b0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","article-title":"Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11","volume":"130","author":"La Fleur","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109560_b0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-023-10778-6","article-title":"Overall Survival in patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation with or without STK11 and\/or KEAP1 Mutations in a Real-World setting","volume":"23","author":"Julian","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109560_b0205","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cells10113129","article-title":"STK11\/LKB1 Modulation of the Immune Response in Lung Cancer: from Biology to Therapeutic Impact","volume":"10","author":"Pons-Tostivint","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.lungcan.2026.109560_b0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","article-title":"STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?","volume":"157","author":"Di Federico","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109560_b0215","doi-asserted-by":"crossref","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200\/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645. PMID: 29337640; PMCID: PMC6075848.","DOI":"10.1200\/JCO.2017.75.3384"},{"key":"10.1016\/j.lungcan.2026.109560_b0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2021.02.010","article-title":"Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab","volume":"154","author":"Shang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109560_b0225","doi-asserted-by":"crossref","unstructured":"Gadgeel SM, Rodriguez-Abreu D, Felip E, Esteban E, Speranza G, Reck M, et al. Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27\u201328 and Jun 22\u201324. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl): Abstract nr LB-397.","DOI":"10.1158\/1538-7445.AM2020-LB-397"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109560_b0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/0008-5472.CAN-23-3682","article-title":"One Mutation to Rule Them all: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling","volume":"84","author":"M\u00fcller","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109560_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the Role of KRAS in Tumor Immune Microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lungcan.2026.109560_b0240","volume":"16(6):OF1","year":"2026","journal-title":"Cancer Discov."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2026.109560_b0245","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"Safety and clinical activity of daraxonrasib (RMC-6236) in RAS-mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109560_b0250","article-title":"Not created Equal: Survival differences by KRAS Mutation Subtype in NSCLC Treated with Immunotherapy","volume":"6","author":"Sun","year":"2025","journal-title":"JTO Clin Res Rep."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2026.109560_b0255","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.1016\/j.annonc.2024.08.1449","article-title":"KRYSTAL-7: a phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRAS G12C mutation","volume":"35","author":"Garassino","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109560_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.018","article-title":"Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of patients with KRAS G12C-mutant Advanced NSCLC","volume":"21","author":"Burns","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109560_b0265","doi-asserted-by":"crossref","unstructured":"Peters S, Hochmair M, Arbour KC, et al. SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. Future Oncol. 2026 Apr;22(9):1073-1082. doi: 10.1080\/14796694.2026.2651961. Epub 2026 Apr 6. PMID: 41940628; PMCID: PMC13064562.","DOI":"10.1080\/14796694.2026.2651961"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109560_b0270","article-title":"Krascendo 2: a phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)","volume":"212","author":"Skoulidis","year":"2026","journal-title":"Lung Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.lungcan.2026.109560_b0275","article-title":"Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1-negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)","volume":"9","author":"Barlesi","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109560_b0280","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.annonc.2022.07.005","article-title":"Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer","volume":"33","author":"Ricciuti","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109560_b0285","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events with Nivolumab Efficacy in Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109560_b0290","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related adverse events Associated with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:53:40Z","timestamp":1789145620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0169500226006215"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109560","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109560"}}